Current position:News > News > Resources
Latest news
Insights
2026-01-22
Will B7-H3 Become the Next Major ADC Target?
The B7-H3 (CD276) ADC field is heating up in 2026. Recent deals—DualityBio & Roche, InnoLake & Ellipses Pharma—highlight global interest and the therapeutic potential of this target.

B7-H3 is overexpressed in multiple solid tumors and contributes to immune evasion. ADCs targeting B7-H3 are showing promising early clinical activity, with several programs advancing into Phase III trials, including YL201, HS-20093, and inatamab deruxtecan. Combination strategies with PD-(L)1 inhibitors are also expanding the potential of this target.
Insights
2025-12-24
IL-5: a key regulator of eosinophilic inflammation
Interleukin-5 (IL-5) is a key driver of eosinophilic inflammation, underlying conditions such as severe asthma, chronic rhinosinusitis with nasal polyps, and other allergic or inflammatory diseases. Recent advances in IL-5–targeted therapies, including GSK’s next-generation ultra-long-acting antibody Depemokimab (Exdensur), are transforming the treatment landscape. With extended dosing intervals and proven efficacy, these therapies offer new hope for improved patient outcomes and quality of life.
Insights
2025-12-24
IL-5: a key regulator of eosinophilic inflammation
Interleukin-5 (IL-5) is a key driver of eosinophilic inflammation, underlying conditions such as severe asthma, chronic rhinosinusitis with nasal polyps, and other allergic or inflammatory diseases. Recent advances in IL-5–targeted therapies, including GSK’s next-generation ultra-long-acting antibody Depemokimab (Exdensur), are transforming the treatment landscape. With extended dosing intervals and proven efficacy, these therapies offer new hope for improved patient outcomes and quality of life.
Message consultation
reset
submit
Message
Message consultation
reset
submit